Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Raised to “Sell” at Wall Street Zen

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms also recently issued reports on MPLT. Weiss Ratings downgraded Maplight Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Jefferies Financial Group reiterated a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, July 27th. HC Wainwright lowered their target price on Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Guggenheim initiated coverage on Maplight Therapeutics in a research report on Monday, October 5th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley downgraded Maplight Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $34.00 to $21.00 in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.20.

Read Our Latest Research Report on Maplight Therapeutics

Maplight Therapeutics Stock Performance

Shares of MPLT stock opened at $5.96 on Friday. Maplight Therapeutics has a 12-month low of $5.93 and a 12-month high of $40.43. The firm’s 50 day moving average is $8.63 and its 200 day moving average is $19.56.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.25. On average, analysts predict that Maplight Therapeutics will post -4.67 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Jonathan Gillis sold 10,167 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $8.08, for a total transaction of $82,149.36. Following the completion of the sale, the chief financial officer owned 142,315 shares of the company’s stock, valued at $1,149,905.20. The trade was a 6.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Erin Pennock Foff sold 15,355 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $8.08, for a total value of $124,068.40. Following the completion of the sale, the insider owned 296,906 shares of the company’s stock, valued at $2,399,000.48. This trade represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 122,974 shares of company stock valued at $990,690. 3.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Maplight Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Maplight Therapeutics by 84.8% in the third quarter. Goldman Sachs Group Inc. now owns 3,599,556 shares of the company’s stock worth $36,679,000 after buying an additional 1,651,244 shares in the last quarter. BlackRock Inc. bought a new position in shares of Maplight Therapeutics in the second quarter worth about $36,741,000. Nan Fung Group Holdings Ltd purchased a new position in shares of Maplight Therapeutics during the 2nd quarter valued at about $34,809,708. 5AM Venture Management LLC purchased a new position in shares of Maplight Therapeutics during the 2nd quarter valued at about $34,048,394. Finally, Baker BROS. Advisors LP grew its stake in shares of Maplight Therapeutics by 219.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,166,763 shares of the company’s stock valued at $11,889,000 after acquiring an additional 802,058 shares during the period.

Maplight Therapeutics Company Profile

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.

Featured Articles

Analyst Recommendations for Maplight Therapeutics (NASDAQ:MPLT)

Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.